| Oct 25 |
Carmakers in Reverse, UBS Moves Ahead: EMEA Earnings Week Ahead
|
| Oct 24 |
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
|
| Oct 24 |
GSK reports positive data for RSV shot in younger, at-risk adults
|
| Oct 24 |
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
|
| Oct 23 |
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
|
| Oct 23 |
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
|
| Oct 21 |
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
|
| Oct 18 |
Trending tickers: Netflix, Ferrari, American Express, Moderna and Boohoo
|
| Oct 16 |
ViiV reports positive real-world data for HIV prevention drug
|
| Oct 16 |
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
|
